BGB-43395 + fulvestrant

BGB-43395 + fulvestrant is an investigational combination therapy under clinical evaluation for advanced solid tumors, particularly hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. BGB-43395 is a highly selective and potent small molecule inhibitor of cyclin-dependent kinase 4 (CDK4), designed to minimize off-target toxicity associated with CDK6 inhibition, such as neutropenia. Fulvestrant is a well-established estrogen receptor antagonist used in the treatment of HR+ breast cancer. The combination aims to target cell cycle progression via CDK4 inhibition while simultaneously blocking estrogen signaling, potentially overcoming resistance mechanisms seen with current therapies and providing benefit in patients who have progressed on prior endocrine and CDK4/6 inhibitor treatments. Early-phase clinical trials are ongoing to determine safety, tolerability, pharmacokinetics, and preliminary efficacy in this patient population[1][3][5][6][7][8].